 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
ARTICLES |
1 ssistant Professor of Pharmacy Practice, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY; Internal Medicine Pharmacotherapy Specialist, Kings County Hospital Center, Brooklyn
2 Assistant Professor of Pharmacy Practice, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University; Clinical Pharmacy Specialist in Ambulatory Care, Bellevue Hospital Center, New York, NY
* To whom correspondence should be addressed. E-mail: david.pham{at}liu.edu.
 |
Abstract |
|---|
OBJECTIVE: To review clinical trials evaluating the safety and efficacy of vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract.
DATA SOURCES: Using the MeSH terms alpha-tocopherol, tocopherols, vitamin E, Parkinson disease, tardive dyskinesia, Alzheimer disease, cataract, and clinical trials, a literature review was conducted to identify peer-reviewed articles in MEDLINE (1966-July 2005).
STUDY SELECTION AND DATA EXTRACTION: Published materials including original research, review articles, and meta-analyses were reviewed. Only English-language articles and trials that included vitamin E alone or in combination with other vitamins or minerals were reviewed. Emphasis was placed on prospective, randomized, double-blind, placebo-controlled clinical trials.
DATA SYNTHESIS: The clinical studies demonstrated contradicting results regarding the benefits of vitamin E in Parkinson's disease, tardive dyskinesia, and cataract. The study reviewed for Alzheimer's disease seemed to show benefit when vitamin E was used; however, the statistical methods employed are questionable. There is enough evidence from large, well-designed studies to discourage the use of vitamin E in Parkinson's disease, cataract, and Alzheimer's disease. We recommend that vitamin E be considered a treatment option in patients with tardive dyskinesia only if they are newly diagnosed.
CONCLUSIONS: We encourage patients to supplement with vitamin E-rich foods. The use of a daily multivitamin, which usually contains 30 IU of alpha-tocopherol, may be beneficial; however, we discourage individual vitamin E supplements that usually contain 400 IU of alpha-tocopherol.
Key Words: alpha-tocopherol, Alzheimer disease, cataract, Parkinson disease, tardive dyskinesia, vitamin E.
Reprints: Dr. Pham, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 75 DeKalb Ave., Brooklyn, NY 11201-5497, fax 718/245-5532, david.pham@liu.edu
This article has been cited by other articles:
|
|
 |
|
  M. Chung, E. M Balk, S. Ip, G. Raman, W. W Yu, T. A Trikalinos, A. H Lichtenstein, E. A Yetley, and J. Lau Reporting of systematic reviews of micronutrients and health: a critical appraisal Am. J. Clinical Nutrition, April 1, 2009; 89(4): 1099 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kenney, C. Hunter, A. Davidson, and J. Jankovic Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia J. Clin. Pharmacol., March 1, 2008; 48(3): 379 - 384. [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
